A multi-center, double-blind, randomized, placebo-controlled, delayed- start phase II/III study to assess the efficacy and safety of Neuro-Cells in (sub)acute spinal cord injury patients
Latest Information Update: 11 Oct 2021
At a glance
- Drugs Autologous neuroregenerative stem cell therapy-Neuroplast (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Neuroplast
Most Recent Events
- 11 Oct 2021 New trial record